Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $44.60

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received a consensus rating of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $44.60.

BLUE has been the topic of several recent research reports. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Barclays decreased their price target on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. Wells Fargo & Company decreased their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. StockNews.com started coverage on bluebird bio in a report on Thursday, May 15th. They set a “sell” rating on the stock. Finally, Baird R W downgraded bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st.

Hedge Funds Weigh In On bluebird bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC grew its position in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares in the last quarter. Groupe la Francaise bought a new position in shares of bluebird bio during the 1st quarter worth $679,000. Goldman Sachs Group Inc. grew its position in shares of bluebird bio by 4.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 64,950 shares of the biotechnology company’s stock worth $317,000 after buying an additional 2,932 shares in the last quarter. Murchinson Ltd. bought a new stake in bluebird bio during the first quarter valued at about $254,000. Finally, Bank of New York Mellon Corp boosted its position in bluebird bio by 12.7% during the first quarter. Bank of New York Mellon Corp now owns 32,759 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 3,686 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Stock Up 0.2%

Shares of BLUE opened at $4.98 on Friday. The stock has a market capitalization of $48.76 million, a price-to-earnings ratio of -0.13 and a beta of 0.27. bluebird bio has a 1 year low of $3.20 and a 1 year high of $28.60. The business’s 50 day simple moving average is $4.27 and its 200-day simple moving average is $6.24. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.